Transcatheter Implantation of Mitral Valve Prostheses: Current Status of the Problem
Author(s) -
I.Yu. Zhuravleva,
Alexander BogachevProkophiev,
Д. П. Демидов,
Alexander Karaskov
Publication year - 2017
Publication title -
kardiologiia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.159
H-Index - 16
eISSN - 2412-5660
pISSN - 0022-9040
DOI - 10.18087/cardio.2017.8.10018
Subject(s) - medicine , cardiology , mitral valve , cardiopulmonary bypass , heart valve , concomitant , mitral valve repair , etiology , mitral valve replacement , heart failure , disease , valve replacement , surgery , stenosis
Mitral valve disease is highly prevalent and quickly leads to development of severe heart failure. Mitral valve disease of degenerative or ischemic etiology affects 7.5 and 9.3% of population older than 65 and 75 years, respectively. "Open" (with cardiopulmonary bypass) surgical repair or valve replacement are not possible in almost half of affected patients because of their complications and concomitant diseases responsible for extremely high risk of these interventions. In the last decade, minimally invasive endovascular technology - transcatheter aortic valve implantation (TAVI) - has been widely introduced for correction of aortic valve disease in similar category of patients. However, transcatheter mitral valve implantation (TMVI) has been developed just during recent couple of years.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom